Filtered By:
Cancer: Skin Cancer
This page shows you your search results in order of relevance. This is page number 3.
Order by Relevance | Date
Total 55943 results found since Jan 2013.
PhRMA Report Shows More than 240 Immuno-Oncology Treatments in Development
In early June 2017, the Pharmaceutical Research and Manufacturers of America (PhRMA) – in partnership with the American Cancer Society Cancer Action Network (ACS CAN) – released a report that found there are over 240 immuno-oncology medicines and vaccines currently in development.
Immuno-oncology treatments are found through research into the role of the body’s immune system in fighting cancer. New immuno-oncology treatment options are allowing the patient’s own immune system to fight cancer similar to the way it fights disease-causing viruses and bacteria. The treatments can help the patient’s own immune system...
Source: Policy and Medicine - July 14, 2017 Category: American Health Authors: Thomas Sullivan - Policy & Medicine Writing Staff Source Type: blogs
Healthcare’s Renewable Resource: Authentic Patient Experience
Cancer is my medical degree. Navigating my way through three distinct cancer diagnoses across three unique stages of life and managing three different treatment paths is my specialty. In the course of enduring Hodgkin’s Lymphoma at age 17, melanoma at 38 and, in 2012, breast cancer at 46, I’ve amassed firsthand expertise in the critical areas of patient-provider communications, care coordination, patient safety, insurance reconciliation, disease prevention, and personalized treatment planning.
From the time of my first cancer diagnosis over 30 years ago to today, cancer has influenced my life and risk of future disease...
Source: Disruptive Women in Health Care - December 4, 2014 Category: Consumer Health News Authors: dw at disruptivewomen.net Tags: Advocacy Cancer Consumer Health Care Patients Source Type: blogs
In precision medicine, pioneering young patient teaches veteran doctor
Allison Schablein seems an unlikely candidate to teach medicine to Mark Kieran. She’s an 8-year-old New Hampshire second grader who loves basketball, hip hop, acrobatic dancing and jewelry. He’s a pediatric neuro-oncologist with a PhD in molecular biology, not to mention decades of clinical and research experience. But teach Kieran, Allison does.
In December 2012, Allison was diagnosed with metastatic anaplastic astrocytoma brain tumors — two on her brain stem, two on her spine, and three at the top of her head. She had surgery and chemotherapy — and for two months her tumors responded to therapy. Then treatment st...
Source: Thrive, Children's Hospital Boston - January 28, 2016 Category: Pediatrics Authors: Irene Sege Tags: Diseases & Conditions Our Patients’ Stories Research Brain tumor Dana-Farber/Boston Children's Cancer and Blood Disorders Center glioma Mark Kieran precision medicine Source Type: news
Allison’ story: Precision medicine, hope and inspiration
We are honored U.S. News & World Report has named Dana-Farber/Boston Children’s Cancer and Blood Disorders Center the #1 pediatric cancer program in the U.S.
As we celebrate this honor, we’re reflecting on some of the greatest children’s stories ever told — stories of the patients and families whose lives touch ours and inspire us.
Allison, a pediatric cancer survivor, is one of those patients.
This hip-hop loving third grader is a pediatric brain tumor survivor and a precision medicine pioneer.
Allison is examined by nurse Maryann Zimmerman.
When Allison’s tumors stopped responding to ...
Source: Thrive, Children's Hospital Boston - June 30, 2016 Category: Pediatrics Authors: Lisa Fratt Tags: Our Patients’ Stories Dana-Farber/Boston Children's Cancer and Blood Disorders Center precision medicine Source Type: news
Allison ’ story: Precision medicine, hope and inspiration
We are honored U.S. News & World Report has named Dana-Farber/Boston Children’s Cancer and Blood Disorders Center the #1 pediatric cancer program in the U.S.
As we celebrate this honor, we’re reflecting on some of the greatest children’s stories ever told — stories of the patients and families whose lives touch ours and inspire us.
Allison, a pediatric cancer survivor, is one of those patients.
This hip-hop loving third grader is a pediatric brain tumor survivor and a precision medicine pioneer.
Allison is examined by nurse Maryann Zimmerman.
When Allison’s tumors stopped responding to ...
Source: Thrive, Children's Hospital Boston - June 30, 2016 Category: Pediatrics Authors: Lisa Fratt Tags: Our Patients’ Stories Dana-Farber/Boston Children's Cancer and Blood Disorders Center precision medicine Source Type: news
Complications in the surgical treatment of pediatric melanoma
Conclusions: In the surgical treatment of pediatric melanoma, the addition of a completion lymph node dissection significantly increases complication risk. Thus, it is critical to determine which patients truly benefit from this procedure.
Source: Journal of Pediatric Surgery - June 1, 2013 Category: Surgery Authors: Paul E. Palmer, Carla L. Warneke, Andrea A. Hayes-Jordan, Cynthia E. Herzog, Dennis P.M. Hughes, Kevin P. Lally, Mary T. Austin Tags: Papers Presented at the 64th Annual Meeting of the Surgical Section of the American Academy of Pediatrics, New Orleans, LA, October 19-21, 2012 Source Type: research
Precision medicine and precision therapeutics: hedgehog signaling pathway, basal cell carcinoma and beyond.
Authors: Mohan SV, Chang AL
Abstract
Precision medicine and precision therapeutics is currently in its infancy with tremendous potential to improve patient care by better identifying individuals at risk for skin cancer and predict tumor responses to treatment. This review focuses on the Hedgehog signaling pathway, its critical role in the pathogenesis of basal cell carcinoma, and the emergence of targeted treatments for advanced basal cell carcinoma. Opportunities to utilize precision medicine are outlined, such as molecular profiling to predict basal cell carcinoma response to targeted therapy and to inform therap...
Source: Seminars in Cutaneous Medicine and Surgery - November 14, 2014 Category: Dermatology Tags: Semin Cutan Med Surg Source Type: research
Pathology and genomics of pediatric melanoma: A critical reexamination and new insights
Abstract
The clinicopathologic features of pediatric melanoma are distinct from those of the adult counterpart. For example, most childhood melanomas exhibit a uniquely favorable biologic behavior, save for those arising in large/giant congenital nevi. Recent studies suggest that the characteristically favorable biologic behavior of childhood melanoma may be related to extreme telomere shortening and dysfunction in the cancer cells. Herein, we review the genomic profiles that have been defined for the different subtypes of pediatric melanoma and particularly emphasize the potential prognostic value of telomerase reverse tr...
Source: Pediatric Blood and Cancer - September 12, 2017 Category: Cancer & Oncology Authors: Armita Bahrami, Raymond L. Barnhill Tags: REVIEW Source Type: research
Pediatric melanoma
Although melanoma is one of the most common malignancies affecting adults, it is a relatively rare disease in children. Melanoma ranks fifth among all cancers in adult males and seventh in adult females, and it is the most common cancer among women 20 to 29 years of age.1 –3 Despite also being the most common skin cancer in children and adolescents, melanoma is still rare in children, with only 300–500 new pediatric diagnoses annually.2,4,5 While the care of adults with melanoma is guided by evidence from multicenter clinical trials, the care of children with mel anoma is limited by the lack of clinical trials specific...
Source: Seminars in Pediatric Surgery - September 19, 2016 Category: Pediatrics Authors: Elisabeth T. Tracy, Jennifer H. Aldrink Source Type: research
Complications of Emerging Oncology Therapies Requiring Treatment in the Pediatric Intensive Care Unit
AbstractPurpose of the ReviewThe development of immunotherapies has resulted in significant improvements in survival for children with cancer and congenital blood disorders. The purpose of this review is to guide the recognition and treatment of significant side of effects three increasingly used immunotherapies —T cell-mediated therapies, immune checkpoint inhibitors, and anti-GD2 antibodies.Recent FindingsCytokine release syndrome (CRS) is a cytokine-induced systemic inflammatory state secondary to chimeric antigen receptor T cells (CAR –T cells), a therapy used for relapsed and refractory leukemia. CRS can range fro...
Source: Current Pediatrics Reports - October 28, 2017 Category: Pediatrics Source Type: research
miR ‑188 suppresses tumor progression by targeting SOX4 in pediatric osteosarcoma.
miR‑188 suppresses tumor progression by targeting SOX4 in pediatric osteosarcoma.
Mol Med Rep. 2018 May 09;:
Authors: Pan L, Meng L, Liang F, Cao L
Abstract
microRNA‑188 (miR‑188) acts as a tumor suppressor in various types of human cancer, including glioma, oral squamous cell carcinoma and hepatocellular carcinoma. However, the function and mechanism of miR‑188 in pediatric osteosarcoma (OS) have yet to be investigated. In the present study reverse transcription‑quantitative polymerase chain reaction revealed that miR‑188 expression was significantly downregulated in pediatric OS tissues a...
Source: Molecular Medicine Reports - May 12, 2018 Category: Molecular Biology Tags: Mol Med Rep Source Type: research
New FDA Watch List: Possible ED Drug-Melanoma Link and MoreNew FDA Watch List: Possible ED Drug-Melanoma Link and More
The FDA said it will study a potential skin cancer signal for phosphodiesterase-5 inhibitors based on recent reports to its FAERS database, a trail other researchers have gone down. Medscape Medical News
Source: Medscape Critical Care Headlines - July 2, 2016 Category: Intensive Care Tags: Family Medicine/Primary Care News Source Type: news
Transcript of Dr. Bihari Video
00:00 to 02.26—Dr. Bihari gives his background and credentials.
Dr. Bihari: My medical training started at Harvard Medical School. I graduated in 1957. Then I trained in Internal Medicine at one of the Harvard teaching hospitals in Boston, Beth Israel, and then in Neurology at Massachusetts General in Boston. Then I went to the National Institutes of Health for two years doing brain physiology—brain research. I did another residency training in Psychiatry in New York, at Columbia Presbyterian Medical Center and then, over the following five or six years, I got very involved in working in Drug Addiction. By 1974, I was...
Source: HONEST MEDICINE: My Dream for the Future - May 16, 2011 Category: Consumer Health News Authors: JuliaS1573 at aol.com (Julia Schopick) Tags: Anecdotal Treatments HONEST MEDICINE Integrative Medicine Low Dose Naltrexone Obituaries Source Type: blogs
Treatment of syncope in tongue cancer with palliative chemotherapy in the intensive care unit: A case report
In this study, we report the case of a 48-year-old male patient who was diagnosed with advanced TC and bilateral cervical lymph node metastasis. On the third day of admission, the patient experienced recurrent syncope with hypotension and bradycardia.
Diagnoses:
The patient was diagnosed with a well-differentiated squamous cell carcinoma of the tongue along with massive cervical lymph node metastasis and carotid sinus syndrome.
Interventions:
Initially, symptomatic treatment of syncope boosted the blood pressure and increased the heart rate. Thereafter, a temporary pacemaker was implanted. Finally, chemotherapy was u...
Source: Medicine - August 1, 2019 Category: Internal Medicine Tags: Research Article: Clinical Case Report Source Type: research
